Navigation Links
Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
Date:11/2/2011

LA JOLLA, Calif., Nov. 2, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that the Australian Patent Office has recently granted claims in the 'Sarnow' patent series for microRNA-122 (miR-122) therapy in the treatment of hepatitis C viral (HCV) infections. The granted claims in Australia extend the reach of the Sarnow patent estate that already covers the use of an anti-miR inhibitor of miR-122 for the treatment of HCV in the United States and Europe. The Sarnow patent series, owned by Stanford University, has been exclusively licensed to Regulus and covers any compound that targets miR-122 for the treatment of HCV in the United States, Europe, and Australia.  

Regulus controls a comprehensive and dominant patent estate related to microRNA therapeutics, including miR-122 therapeutic agents. Specifically for miR-122, Regulus controls the following:

  • The 'Sarnow' patent estate claiming the use of anti-miR-122 to treat HCV infection, as a single therapeutic agent or in combination with other HCV therapeutic agents (US Patent No. 7,307,067; US Patent No. 7,838,504; EP Patent No. 1 747 023; and Australian Patent Application No. 2005240118 recently accepted for grant);
  • The 'Esau' patent claiming the use of anti-miRs targeting miR-122 as inhibitory agents (US Patent No. 7,683,036);
  • The 'Tuschl III' patent claiming compositions of matter for miR-122 and complementary oligonucleotides (US Patent No. 7,232,806);
  • The 'Manoharan' patent claiming antagomirs, including antagomirs targeting miR-122 (US Patent No. 7,582,744); and
  • A Regulus-owned European patent claiming the use of miR-122 antagonists for reducing cholesterol (EP 1 931 782).

"We are pleased with the recent allowance of miR-122 claims in Au
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Webinar Advisory: Regulus to Host Discussion About Potential of microRNA-33 as Target for Treatment of Atherosclerosis
2. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
3. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
4. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
5. Echo Therapeutics Announces Warrant Exercise by Its Largest Shareholder
6. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
7. Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
10. Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018
11. Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... FREMONT, Calif. , May 5, 2015 /PRNewswire/ ... clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and ... 2a clinical trial evaluating tenapanor in Stage 3 ... mellitus and albuminuria did not meet the primary ... tenapanor-treated patients compared to patients receiving placebo. ...
(Date:5/5/2015)... , May 5, 2015 /CNW Telbec/ - ... Laval and known under the « ... the closing of the transaction previously announced on April ... issued and outstanding  shares of Orthoconcept (2008) inc.   ... 500 000 common shares (TSXV: ERG) to the vending ...
(Date:5/5/2015)... -- The preclinical contract research organization Absorption Systems , ... safety testing of medical devices, announces that Dr. ... at this week,s annual meeting of The Association for ... Denver, CO. The title of Dr. Gum,s ... Bio-Absorbable Carboxymethyl Hyaluronic Acid (CMHA) Polymer in a Rabbit ...
Breaking Medicine Technology:Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 2Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 3Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3
... aureus and, Methicillin-Resistant Staphylococcus aureus from Positive ... BD Diagnostics, a segment,of BD (Becton, Dickinson and ... it,received clearance from the U.S. Food and Drug ... new assay is the first test available to,rapidly ...
... Dec. 27 Allos,Therapeutics, Inc. (Nasdaq: ALTH ... (DMC) has completed the pre-specified 65-patient,safety review of ... trial of,PDX (pralatrexate) in patients with relapsed or ... the trial continue per the,protocol. This interim assessment ...
Cached Medicine Technology:BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures 2BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 2Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 4Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 5
(Date:5/5/2015)... With the FCPX LUT: Monochromatic pack from Pixel ... color grades to footage. A LUT is a Lookup Table ... LUT changes every pixel's color to the corresponding color indicated ... LUT files. , This plugin was inspired by indie films ... washed look. , CUBE LUT files are extremely versatile. ...
(Date:5/5/2015)... Indian Trail, NC (PRWEB) May 05, 2015 ... firm serving Indian Trail, Monroe, Matthews, Charlotte and surrounding ... in the field of accounting. This company provides assistance ... a priority as they prepare individual or corporate tax ... a system in the cloud that allows clients (and ...
(Date:5/5/2015)... York, NY (PRWEB) May 05, 2015 ... Health IVF Clinic in Greece, an experienced team ... and treatment of infertility for patients around the globe. ... partnered with VisitandCare.com. Greece unquestionably remains a global leader ... most talented and hard-working fertility specialists in the world ...
(Date:5/5/2015)... 2015 From the halls of ... leader in enabling enterprise collaboration across platforms and ... speed up and simplify the move to Microsoft ... Solutions for Office 365 enable organizations to ... sustainable user adoption and effectively managing critical business ...
(Date:5/5/2015)... Dr. Patricia George knows all too well the ... pulmonary hypertension specialist at the University of Pittsburgh Medical ... an initial idea entered her mind for Team PHenomenal ... at the 2010 PHA International Conference,” George recalled. “The ... recalling their climb up Mt. Kilimanjaro and I remember ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Announced the Release of FCPX LUT Monochromatic 2Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 2Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 3Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 2Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 3Health News:World PH Day: Team PHenomenal Hope Races to Spread the Word about Pulmonary Hypertension 2
... point out , , TUESDAY, Dec. 2 (HealthDay News) -- A ... wallets but on their health as well, a new survey ... to costs, according to a Harris Interactive poll released Tuesday ... U.S. Department of Health and Human Services. , That means ...
... A long history of terrorism in India precedes the ... (GTD), maintained at the University of Maryland by the ... to Terrorism (START) counts more than 4,100 terrorist attacks ... This information is freely available online. , The GTD ...
... News/ -- EIN News has announced the launch of a new ... , With new advances in medicine, more and ... key components to surviving cancer. , ... about prostate cancer, its risk factors, screening procedures and drugs to ...
... Colo., Dec. 2 MicroPhage, Inc., http://www.microphage.com , announced ... Board of Directors. Taussig was president and CEO ... nation,s leading institution,for studying respiratory diseases, from 1993 to ... "I have followed MicroPhage ...
... worldwide leader in the,development, distribution and use of minimally ... of India HIFU and,the launch of Sonablate(R) HIFU services ... treatment of prostate disease. , ... Nephrology Services at the,hospital said, "The introduction of the ...
... T Zone? It is the mucous membranes of your eyes, nose ... enter your body and grow to make you sick. Touching ... contamination, eye rubbing, nose picking, nail biting and many other descriptors. ... help reduce flu and flu-like illness this winter. It is ...
Cached Medicine News:Health News:Economy Driving Women to Skimp on Health Care: Poll 2Health News:Economy Driving Women to Skimp on Health Care: Poll 3Health News:India terrorism by the numbers 2Health News:EIN News Introduces 'Prostate Cancer News Today'; Website Offers Information on Risk Factors, Treatment, Drugs 2Health News:MicroPhage Selects Lynn Taussig, MD for Board of Directors 2Health News:USHIFU Announces First Sonablate(R) HIFU Device in India for Minimally Invasive Prostate Cancer Treatment 2Health News:Dr. Will Sawyer and Henry the Hand Champion Handwasher Have Discovered How to PREVENT the Flu and Common Cold!! DO NOT TOUCH the T Zone! 2
The First Check Home Drug Test is the first over-the counter, FDA approved home drug test that provides immediate information about the possible use of prescription drugs....
The ToxCup Drug Screen Cup is a one-step test for the rapid detection of up to five drugs of abuse and four adulteration tests. It's design integrates sample collection, drug/adulteration testing and...
Lasts up to 3 months , Absorbable copolymer of glycolic acid and trimethylene carbonate , Designed to provide relief from short term dry eye conditions. , Appropriate for surgery-related d...
... transconjunctival self-retaining infusion cannulas for use in ... some benefit to patients that present with ... lessening the occurrence of suture induced astigmatism. ... and does not require a blade for ...
Medicine Products: